CUSIP 055477103 · who reports it, how much, and how much it matters to them
16 of the 720 hedge fund managers we track reported shares of Bicara Therapeutics Inc. (Nasdaq: BCAX) on Form 13F for 30 June 2026. Between them they reported USD 430m. The largest position belongs to Ra Capital Management, at USD 215m. The manager with the most riding on it is Palo Alto Investors, where it is 2.3% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Ra Capital Management1 fund on PPLI.com | USD 215m | 1.9% |
| 2 | Deep Track Capital1 fund on PPLI.com | USD 122m | 1.8% |
| 3 | Palo Alto Investors6 funds on PPLI.com | USD 16m | 2.3% |
| 4 | Rock Springs Capital Management2 funds on PPLI.com | USD 16m | 0.8% |
| 5 | D. E. Shaw & Co.15 funds on PPLI.com | USD 15m | 0.0% |
| 6 | Walleye Capital8 funds on PPLI.com | USD 10m | 0.0% |
| 7 | Dafna Capital Management6 funds on PPLI.com | USD 8.5m | 1.6% |
| 8 | Millennium Management6 funds on PPLI.com | USD 7.8m | 0.0% |
| 9 | Citadel Advisors32 funds on PPLI.com | USD 6.3m | 0.0% |
| 10 | Orbimed Advisors1 fund on PPLI.com | USD 5.7m | 0.1% |
| 11 | Hudson Bay Capital Management8 funds on PPLI.com | USD 3.1m | 0.0% |
| 12 | Burkehill Global Management5 funds on PPLI.com | USD 1.5m | 0.1% |
| 13 | Two Sigma Investments35 funds on PPLI.com | USD 1.4m | 0.0% |
| 14 | Aquatic Capital Management3 funds on PPLI.com | USD 538,000 | 0.0% |
| 15 | Engineers Gate Manager1 fund on PPLI.com | USD 499,000 | 0.0% |
| 16 | Voleon Capital Management13 funds on PPLI.com | USD 349,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Palo Alto Investors | USD 16m | 2.3% |
| 2 | Ra Capital Management | USD 215m | 1.9% |
| 3 | Deep Track Capital | USD 122m | 1.8% |
| 4 | Dafna Capital Management | USD 8.5m | 1.6% |
| 5 | Rock Springs Capital Management | USD 16m | 0.8% |
| 6 | Orbimed Advisors | USD 5.7m | 0.1% |
| 7 | Burkehill Global Management | USD 1.5m | 0.1% |
| 8 | Walleye Capital | USD 10m | 0.0% |
| 9 | Aquatic Capital Management | USD 538,000 | 0.0% |
| 10 | Hudson Bay Capital Management | USD 3.1m | 0.0% |
Bicara Therapeutics Inc. trades under the symbol BCAX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 055477103.
16 of the 720 hedge fund managers PPLI.com tracks reported Bicara Therapeutics Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Ra Capital Management (USD 215m), Deep Track Capital (USD 122m), Palo Alto Investors (USD 16m), Rock Springs Capital Management (USD 16m) and D. E. Shaw & Co. (USD 15m).
16 managers in our coverage reported it, and between them they run 143 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Palo Alto Investors, where the position was 2.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Bicara Therapeutics Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.